Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eagle Pharmaceuticals, Inc. (EGRX : NSDQ)

• Company Description    Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $47.07 Daily Weekly Monthly 20 Day Moving Average: 124,229 shares Shares Outstanding: 12.70 (millions) Market Capitalization: $597.72 (millions) Beta: 0.68 52 Week High: $58.25 52 Week Low: $36.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.92% 2.67% 12 Week -2.73% 2.41% Year To Date -7.56% 7.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 50 TICE BOULEVARD SUITE 315 - WOODCLIFF LAKE,NJ 07677 USA ph: 201-326-5300 fax: - investors@eagleus.com http://www.eagleus.com

• General Corporate Information    Officers Scott Tarriff - Chief Executive Officer; President and Director Michael Graves - Chairman Brian Cahill - Chief Financial Officer Steven Ratoff - Director Jennifer K. Simpson - Director Peer Information Eagle Pharmaceuticals, Inc. (BJCT) Eagle Pharmaceuticals, Inc. (CADMQ) Eagle Pharmaceuticals, Inc. (APNO) Eagle Pharmaceuticals, Inc. (UPDC) Eagle Pharmaceuticals, Inc. (IMTIQ) Eagle Pharmaceuticals, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 269796108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 12.70 Most Recent Split Date: (:1) Beta: 0.68 Market Capitalization: $597.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $2.48 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $8.22 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: 5.73 Trailing 12 Months: 16.99 PEG Ratio: - Price Ratios Price/Book: 2.77 Price/Cash Flow: - Price / Sales: 2.43 EPS Growth vs. Year Ago Period: 11,466.67% vs. Previous Quarter: 810.42% Sales Growth vs. Year Ago Period: 180.91% vs. Previous Quarter: 173.80% ROE 03/31/22 - 18.56 12/31/21 - -4.62 09/30/21 - 2.97 ROA 03/31/22 - 13.10 12/31/21 - -3.34 09/30/21 - 2.18 Current Ratio 03/31/22 - 2.36 12/31/21 - 2.32 09/30/21 - 3.55 Quick Ratio 03/31/22 - 2.12 12/31/21 - 2.03 09/30/21 - 3.35 Operating Margin 03/31/22 - 14.56 12/31/21 - -5.03 09/30/21 - 3.14 Net Margin 03/31/22 - 14.56 12/31/21 - -5.03 09/30/21 - 3.14 Pre-Tax Margin 03/31/22 - 21.03 12/31/21 - -2.65 09/30/21 - 3.13 Book Value 03/31/22 - 17.01 12/31/21 - 13.66 09/30/21 - 14.15 Inventory Turnover 03/31/22 - 3.67 12/31/21 - 3.64 09/30/21 - 5.21 Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.11 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 9.52

Powered by Zacks Investment Research ©